Cipher Pharmaceuticals Inc. (OTCMKTS:CPHRF) Sees Significant Increase in Short Interest

Cipher Pharmaceuticals Inc. (OTCMKTS:CPHRF) (TSE:CPH) saw a large growth in short interest in the month of August. As of August 31st, there was short interest totalling 30,600 shares, a growth of 58.5% from the August 15th total of 19,300 shares. Based on an average trading volume of 73,800 shares, the short-interest ratio is currently 0.4 days.

Cipher Pharmaceuticals Stock Down 12.6 %

Shares of CPHRF stock traded down $1.65 during mid-day trading on Friday, hitting $11.47. The stock had a trading volume of 498,072 shares, compared to its average volume of 20,042. Cipher Pharmaceuticals has a fifty-two week low of $2.50 and a fifty-two week high of $14.60. The company’s 50-day simple moving average is $9.84 and its 200-day simple moving average is $7.50.

Cipher Pharmaceuticals Company Profile

Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.